PT

JCB and AEON Credit Service Indonesia Launch the AEON JCB Precious Card

Retrieved on: 
Friday, March 22, 2024
AEON, Gasoline, IDR, JCB Co., Ltd., Travel, Restaurant, Eid al-Fitr, JCB, Platinum, Financial services

TOKYO & JAKARTA, Mar 22, 2024 - (JCN Newswire) - PT JCB International Indonesia, a subsidiary of JCB International Co., Ltd. (JCB), and PT AEON Credit Service Indonesia have launched the AEON JCB Precious Card, targeting the premium segment and focusing on family needs.

Key Points: 
  • TOKYO & JAKARTA, Mar 22, 2024 - (JCN Newswire) - PT JCB International Indonesia, a subsidiary of JCB International Co., Ltd. (JCB), and PT AEON Credit Service Indonesia have launched the AEON JCB Precious Card, targeting the premium segment and focusing on family needs.
  • Customers can easily apply for the AEON JCB Precious Card and approved applicants receive the card within one hour at the AEON Service Counter at all AEON Malls in Indonesia.
  • Takumi Takahashi, President Director, PT JCB International Indonesia, said, "JCB is proud to partner with AEON Credit Service Indonesia and launch the AEON JCB Precious Card, offering its cardmembers benefits for daily needs, shopping, dining, domestic and international travel.
  • We hope that the AEON JCB Precious cardmembers can enjoy the experience of a complete journey with the AEON JCB Precious Card."

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Wednesday, May 8, 2024
Vaccination, Public, Advisory Committee, Net, Ageing, Tolerability, Investment, PCV15, PCV, Safety, Phase 10, Infant, Infection, Trial of the century, Conference, Growth, Administration, Lonza, Immunization, Exercise, Research and development, Bank, ACIP, Stage 2, Initiate, PCV20, G&A, SAN, End, Genetically modified bacteria, IPD, Vaccine

SAN CARLOS, Calif., May 08, 2024 (GLOBE NEWSWIRE) --  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • “We also continue to progress our early-stage pipeline led by VAX-A1, a vaccine candidate designed to prevent Group A Strep infections.
  • The aggregate gross proceeds to Vaxcyte from this offering were $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • The March 31, 2024 amount includes the $816.5 million in net proceeds from the follow-on offering completed in February 2024.
  • As of March 31, 2024, Vaxcyte had incurred $101.8 million in total capital and facility buildout expenditures that were reflected on the Company’s balance sheet as of that date.

Verizon’s Small Business Digital Ready program reaches 300K businesses with free, online resources

Retrieved on: 
Wednesday, May 8, 2024
Prosperity, Small business, Digital inclusion, Climate, LISC, VZ, Verizon Communications, RSS, Partnership, Local Initiatives Support Corporation, Marketing, Verizon Business

Of the 300,000 businesses Small Business Digital Ready has reached, 51% are women-owned, 62% are Black-owned or Hispanic-owned businesses, and 40% have been in business for 2 years or less - often the most precarious time for new small businesses.

Key Points: 
  • Of the 300,000 businesses Small Business Digital Ready has reached, 51% are women-owned, 62% are Black-owned or Hispanic-owned businesses, and 40% have been in business for 2 years or less - often the most precarious time for new small businesses.
  • Rose Stuckey Kirk, Verizon’s Chief Corporate Social Responsibility Officer, said, “Verizon is leveraging its technology and innovation to promote economic empowerment and enable communities to thrive through Small Business Digital Ready.
  • Verizon Small Business Digital Ready provides personalized tools and resources in partnership with Local Initiatives Support Corporation (LISC) and Next Street.
  • Small Business Digital Ready is part of Citizen Verizon, the company’s responsible business plan for economic, environmental and social advancement.

B2Gold Reports Q1 2024 Results; Cash Operating Costs and All-In Sustaining Costs Below 2024 Annual Guidance Ranges; Update on Goose Project Following Successful Completion of 2024 Winter Ice Road Campaign

Retrieved on: 
Tuesday, May 7, 2024
Sale, PEA, Antelope, KIA, PIN, AngloGold Ashanti, Bed, Kitikmeot Region, MLA, Umwelt, Echo, Water, Capital expenditure, Public expenditure, Life, Gold, Steel, Farm, Otjikoto Lake, WIR, Bank statement, Mining, Calendar, Government, Uranium mining

Cash operating costs (see “Non-IFRS Measures”) for the first quarter of 2024 were $642 per gold ounce produced ($561 per ounce gold sold).

Key Points: 
  • Cash operating costs (see “Non-IFRS Measures”) for the first quarter of 2024 were $642 per gold ounce produced ($561 per ounce gold sold).
  • All-in sustaining costs (see “Non-IFRS Measures”) for the first quarter of 2024 were $958 per gold ounce sold.
  • The lower sustaining capital expenditures were mainly a result of timing of expenditures and are expected to be incurred later in 2024.
  • Under B2Gold management, the 2,100 loads completed during the 2024 WIR campaign is approximately double the loads completed during the 2023 WIR campaign.

Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

Retrieved on: 
Tuesday, May 7, 2024
Standard of care, Bank, Conference, Interest

MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, NV.

Key Points: 
  • MENLO PARK, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will present at the upcoming Bank of America Healthcare Conference, in Las Vegas, NV.
  • Sight Sciences’ management is scheduled to present on Tuesday, May 14, 2024, at 8:15 am PT / 11:15 am ET.
  • Interested parties may access a live and archived webcast of the fireside chat on the “Investors” section of the company’s website at: investors.sightsciences.com .

Alimera Announces Scientific Data Highlighting YUTIQ® to be Presented at Upcoming Association for Research in Vision and Ophthalmology and Retina World Congress Conferences

Retrieved on: 
Tuesday, May 7, 2024
Research, RWC, Aqueous humour, Patient, Physician, Alimera Sciences, ARVO

ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmology (ARVO) conference, scheduled in Seattle, WA.

Key Points: 
  • ATLANTA, May 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today it will have three scientific abstracts at two upcoming ophthalmic congresses including the Association for Research in Vision and Ophthalmology (ARVO) conference, scheduled in Seattle, WA.
  • from May 5 - 9 and Retina World Congress (RWC) scheduled in Fort Lauderdale, FL.
  • from May 9 - 13.
  • Tue, May 07 8:30am - 10:15am PT; Tedi Begaj, MD; Lisa Faia, MD
    Thu, May 09 2:30pm - 2:45pm PT; Phoebe Lin, MD
    36-month Outcomes Following Treatment of Chronic Non-infectious Uveitis Affecting the Posterior Segment with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant: a CALM Registry Analysis

Alarm.com to Participate in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 8, 2024
Home Goods, Audio, Video, Hardware, Technology, Apps, Applications, IOT (Internet of Things), Retail, Security, ALRM, Software, Conference, Fireside chats, Cryptocurrency

Alarm.com Holdings, Inc. (Nasdaq: ALRM), the leading platform for the intelligently connected property, today announced that Steve Valenzuela, Chief Financial Officer, will participate in and host one-on-one investor meetings at the following upcoming investor conferences.

Key Points: 
  • Alarm.com Holdings, Inc. (Nasdaq: ALRM), the leading platform for the intelligently connected property, today announced that Steve Valenzuela, Chief Financial Officer, will participate in and host one-on-one investor meetings at the following upcoming investor conferences.
  • 52nd Annual J.P. Morgan Global Technology, Media and Communications Conference - Boston, MA
    Fireside Chat at 9:30 a.m.
  • ET
    Bank of America Global Technology Conference – San Francisco, CA
    Fireside Chat at 8:40 a.m. PT
    Jefferies Software Conference – Newport, CA

Guardant Health to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, May 7, 2024
Biotechnology, Health, Pharmaceutical, Health Technology, Oncology, SVB Securities, Conference, Fireside chats, Communications satellite

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.

Key Points: 
  • Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will participate in the following investor conferences.
  • Fireside Chat on Wednesday, May 15 at 10:40 a.m. PT / 1:40 p.m.
  • ET
    Leerink Partners 2024 Healthcare Crossroads Conference in Austin, Texas
    Fireside Chat on Wednesday, May 29 at 3:00 p.m. CT / 4:00 p.m.
  • ET
    Interested parties may access live and archived webcasts of the sessions on the “Investors” section of the company website at: www.guardanthealth.com .

Avidity Biosciences to Participate in Upcoming Investor Conference

Retrieved on: 
Wednesday, May 8, 2024
Bank of America, BofA Securities, Therapy, RNA, Conference, SAN

SAN DIEGO, May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:

Key Points: 
  • SAN DIEGO, May 8, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will be participating in the following upcoming conference:
    BofA Securities 2024 Health Care Conference on May 15 at 8:00 a.m. PT / 11:00 a.m.
  • ET
    A live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations .

Illumina publicly files Form 10 registration statement ahead of planned divestiture of GRAIL

Retrieved on: 
Monday, May 6, 2024
Capital market, European Commission, IRS, Growth, Civil service commission, SAN, Q&A, Security (finance)

SAN DIEGO, May 6, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that it has publicly filed a Form 10 registration statement with the U.S. Securities and Exchange Commission ("SEC"), in connection with its intended divestiture of GRAIL. A version of this registration statement was submitted to the SEC last December as required.

Key Points: 
  • A version of this registration statement was submitted to the SEC last December as required.
  • The Form 10 includes detailed information about GRAIL, including historic financial information, a description of GRAIL's business and strategy, and other legal and financial disclosures.
  • This filing is a necessary step for a capital markets transaction; however, it is not an indication of the means by which Illumina will ultimately divest GRAIL.
  • "Illumina remains committed to divesting GRAIL expeditiously, and on terms consistent with our divestment plan, which was approved by the European Commission.